Transplant-associated hyperglycemia: A new look at an old problem

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 2, 2007, Pages 343-355

  Crutchlow, Michael F ^a   Bloom, Roy D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; HYPERGLYCEMIA; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X; REVIEW;

HUMANS; HYPERGLYCEMIA; KIDNEY TRANSPLANTATION; METABOLIC SYNDROME X;

EID: 34548856248     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03671106     Document Type: Review

References (132)

1. Callaghan CJ, Bradley JA: Current status of renal transplantation. Methods Mol Biol 333: 1-28, 2006
2. Davidson J, Wilkinson A, Dantal J, Dotta F, Haller H, Hernandez D, Kasiske BL, Kiberd B, Krentz A, Legendre C, Marchetti P, Markell M, van der Woude FJ, Wheeler DC, International Expert Panel: New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 75: SS3-SS24, 2003
3. Standards of medical care in diabetes - 2006. Diabetes Care 29[Suppl 1]: S4-S42, 2006
4. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet 354: 617-621, 1999
5. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 22: 920-924, 1999
6. Saydah SH, Loria CM, Eberhardt MS, Brancati FL: Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 24: 447-453, 2001
7. Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E: Fasting blood glucose: An underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. Diabetes Care 22: 45-49, 1999
8. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD: New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67: 2415-2421, 2005
9. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161: 397-405, 2001
10. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 178-185, 2003
11. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, Woodworth TG, Brennan DC: Incidence and cost of new onset diabetes mellitus among US wait-listed and transplanted renal allograft recipients. Am J Transplant 3: 590-598, 2003
12. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC: Posttransplantation diabetes: A systematic review of the literature. Diabetes Care 25: 583-592, 2002
13. Hebert PL, Geiss LS, Tierney EF, Engelgau MM, Yawn BP, McBean AM: Identifying persons with diabetes using Medicare claims data. Am J Med Qual 14: 270-277, 1999
14. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB: Beta-cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 71: 1417-1423, 2001
15. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403, 2002
16. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azen SP: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51: 2796-2803, 2002
17. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350, 2001
18. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368: 1096-1105, 2006
19. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359: 2072-2077, 2002
20. Executive summary of the third report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285: 2486-2497, 2001
21. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288: 2709-2716, 2002
22. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001
23. Whelton PK, Perneger TV, He J, Klag MJ: The role of blood pressure as a risk factor for renal disease: A review of the epidemiologic evidence. J Hum Hypertens 10: 683-689, 1996
24. Humphrey LL, Ballard DJ, Frohnert PP, Chu CP, O'Fallon WM, Palumbo PJ: Chronic renal failure in non-insulin-dependent diabetes mellitus. A population-based study in Rochester, Minnesota. Ann Intern Med 111: 788-796, 1989
25. Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, Whelton PK, He J: The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 140: 167-174, 2004
26. Palaniappan L, Carnethon M, Fortmann SP: Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 16: 952-958, 2003
27. Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM: One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 5: 2922-2928, 2005
28. Armstrong KA, Campbell SB, Hawley CM, Nicol DL, Johnson DW, Isbel NM: Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 5: 2710-2718, 2005
29. de Vries AP, Bakker SJ, van Son WJ, van der Heide JJ, Ploeg RJ, The HT, de Jong PE, Gans RO: Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 4: 1675-1683, 2004
30. Porrini E, Delgado P, Bigo C, Alvarez A, Cobo M, Checa MD, Hortal L, Fernandez A, Garcia JJ, Velazquez S, Hernandez D, Salido E, Torres A: Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 48: 134-142, 2006
31. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112-S119, 1998
32. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
33. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B: Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 4: 1662-1668, 2004
34. Zoungas S, Kerr PG, Chadban S, Muske C, Ristevski S, Atkins RC, McNeil JJ, McGrath BP: Arterial function after successful renal transplantation. Kidney Int 65: 1882-1889, 2004
35. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11: 1735-1743, 2000
36. Kasiske BL: Epidemiology of cardiovascular disease after renal transplantation. Transplantation 72[Suppl]: S5-S8, 2001
37. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM: Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 15: 89-94, 2001
38. Cosio FG, Pesavento TE, Kim S, Osei K, Henry M, Ferguson RM: Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 62: 1440-1446, 2002
39. Lentine KL, Brennan DC, Schnitzler MA: Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 16: 496-506, 2005
40. Ducloux D, Kazory A, Chalopin JM: Posttransplant diabetes mellitus and atherosclerotic events in renal transplant recipients: A prospective study. Transplantation 79: 438-443, 2005
41. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653, 2005
42. McCance DR, Hanson RL, Charles MA, Jacobsson LT, Pettitt DJ, Bennett PH, Knowler WC: Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 308: 1323-1328, 1994
43. Engelgau MM, Thompson TJ, Herman WH, Boyle JP, Aubert RE, Kenny SJ, Badran A, Sous ES, Ali MA: Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes. Diagnostic criteria and performance revisited. Diabetes Care 20: 785-791, 1997
44. Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW: Glycemic control and coronary heart disease risk in persons with and without diabetes: The atherosclerosis risk in communities study. Arch Intern Med 165: 1910-1916, 2005
45. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of hemoglobin A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk. Ann Intern Med 141: 413-420, 2004
46. Porte D Jr: Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complications. Diabetes Metab Res Rev 17: 181-188, 2001
47. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B, Jardine A, Levitt N, Marchetti P, Markell M, Naicker S, O'Connell P, Schnitzler M, Standl E, Torregosa JV, Uchida K, Valantine H, Villamil F, Vincenti F, Wissing M: Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 19: 291-298, 2005
48. Olefsky JM, Johnson J, Liu F, Jen P, Reaven GM: The effects of acute and chronic dexamethasone administration on insulin binding to isolated rat hepatocytes and adipocytes. Metabolism 24: 517-527, 1975
49. Olefsky JM: Effect of dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest 56: 1499-1508, 1975
50. Magnuson MA, Quinn PG, Granner DK: Multihormonal regulation of phosphoenolpyruvate carboxykinase-chloramphenicol acetyltransferase fusion genes. Insulin's effects oppose those of cAMP and dexamethasone. J Biol Chem 262: 14917-14920, 1987
51. David DS, Cheigh JS, Braun DW Jr, Fotino M, Stenzel KH, Rubin AL: HLA-A28 and steroid-induced diabetes in renal transplant patients. JAMA 243: 532-533, 1980
52. Arner P, Gunnarsson R, Blomdahl S, Groth CG: Some characteristics of steroid diabetes: A study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 6: 23-25, 1983
53. Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KM: Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 5: 196-202, 1985
54. Haririan A, Sillix DH, Morawski K, El-Amm JM, Garnick J, Doshi MD, West MS, Gruber SA: Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant 6: 2396-2402, 2006
55. Sivaraman P, Nussbaumer G, Landsberg D: Lack of long-term benefits of steroid withdrawal in renal transplant recipients. Am J Kidney Dis 37: 1162-1169, 2001
56. Borrows R, Chan K, Loucaidou M, Lawrence C, Van Tromp J, Cairns T, Griffith M, Hakim N, McLean A, Palmer A, Papalois V, Taube D: Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil. Transplantation 81: 125-128, 2006
57. Heilman RL, Mazur MJ, Reddy KS, Moss A, Post D, Mulligan D: Steroid avoidance immunosuppression in low-risk kidney transplant recipients. Transplant Proc 37: 1785-1788, 2005
58. Midtvedt K, Hjelmesaeth J, Hartmann A, Lund K, Paulsen D, Egeland T, Jenssen T: Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal. J Am Soc Nephrol 15: 3233-3239, 2004
59. Kandaswamy R, Melancon JK, Dunn T, Tan M, Casingal V, Humar A, Payne WD, Gruessner RW, Dunn DL, Najarian JS, Sutherland DE, Gillingham KJ, Matas AJ: A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients: An interim analysis. Am J Transplant 5: 1529-1536, 2005
60. Khwaja K, Asolati M, Harmon JV, Melancon JK, Dunn TB, Gillingham KJ, Kandaswamy R, Humar A, Gruessner RW, Payne WD, Najarian JS, Dunn DL, Sutherland DE, Matas AJ: Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation 78: 1397-1399, 2004
61. Khwaja K, Asolati M, Harmon, J, Melancon JK, Dunn T, Gillingham K, Kandaswamy R, Humar A, Gruessner R, Payne W, Najarian J, Dunn D, Sutherland D, Matas AJ: Outcome at 3 years with a prednisone-free maintenance regimen: A single-center experience with 349 kidney transplant recipients. Am J Transplant 4: 980-987, 2004
62. Axelrod D, Leventhal JR, Gallon LG, Parker MA, Kaufman DB: Reduction of CMV disease with steroid-free inummosuppression in simultaneous pancreas-kidney transplant recipients. Am J Transplant 5: 1423-1429, 2005
63. Laftavi MR, Stephan R, Stefanick B, Kohli R, Dagher F, Applegate M, O'Keefe J, Pierce D, Rubino A, Guzowski H, Leca N, Dayton M, Pankewycz O: Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 137: 364-371, 2005
64. Rike A, Mogilishetty G, Alloway R, Cardi M, Roy-Chaudhury P, Succop P, Buell J, Woodle E: Metabolic Syndrome in Renal Transplantation: Comparison of Early Corticosteroid Withdrawal Versus Chronic Corticosteroid Therapy [Abstract], World Transplant Congress, Boston, MA, July 22 to 27, 2006
65. Augustine J, Hricik D: Steroid sparing in kidney transplantation: Changing paradigms, improving outcomes, and remaining questions. Clin J Am Soc Nephrol 1: 1080-1089, 2006
66. Heit JJ, Apelqvist AA, Gu X, Winslow MM, Neilson JR, Crabtree GR, Kim SK: Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 443: 345-349, 2006
67. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP: Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 98: 2786-2793, 1996
68. Herold KC, Nagamatsu S, Buse JB, Kulsakdinun P, Steiner DF: Inhibition of glucose-stimulated insulin release from beta TC3 cells and rodent islets by an analog of FK506. Transplantation 55: 186-192, 1993
69. Hahn HJ, Dunger A, Laube F, Besch W, Radloff E, Kauert C, Kotzke G: Reversibility of the acute toxic effect of cyclosporin A on pancreatic B cells of Wistar rats. Diabetologia 29: 489-494, 1986
70. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 344: 423-428, 1994
71. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63: 977-983, 1997
72. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM: Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 59: 732-737, 2001
73. Mayer AD, Dmitrewski J, Squifflet JP, Besse T, Grabensee B, Klein B, Eigler FW, Heemann U, Pichlmayr R, Behrend M, Vamenterghem Y, Donck J, van Hooff J, Christiaans M, Morales JM, Andres A, Johnson RW, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe JL, Talbot D, Pohanka E, et al.: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 64: 436-443, 1997
74. Miller J, Mendez R, Pirsch JD, Jensik SC: Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 69: 875-880, 2000
75. Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C 3rd, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE: Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69: 834-841, 2000
76. Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP: Influence of tacrolimus on glucose metabolism before and after renal transplantation: A prospective study. J Am Soc Nephrol 12: 583-588, 2001
77. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP: Glucose metabolism in renal transplant recipients on tacrolimus: The effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 13: 221-227, 2002
78. Filler G, Neuschulz I, Vollmer I, Amendt P, Hocher B: Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients. Nephrol Dial Transplant 15: 867-871, 2000
79. van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP: Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 13: 213-220, 2002
80. Knight RJ, Kahan BD: The place of sirolimus in kidney transplantation: Can we reduce calcineurin inhibitor renal toxicity? Kidney Int 70: 994-999, 2006
81. Teutonico A, Schena PF, Di Paolo S: Glucose metabolism in renal transplant recipients: Effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 16: 3128-3135, 2005
82. Romagnoli J, Citterio F, Nanni G, Favi E, Tondolo V, Spagnoletti G, Salerno MP, Castagneto M: Incidence of post-transplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine. Transplant Proc 38: 1034-1036, 2006
83. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J: Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72: 777-786, 2001
84. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattstrom C, Lebranchu Y, Vialtel P: Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 69: 1252-1260, 2000
85. Syed NA, Khandelwal RL: Reciprocal regulation of glycogen phosphorylase and glycogen synthase by insulin involving phosphatidylinositol-3 kinase and protein phosphatase-1 in HepG2 cells. Mol Cell Biochem 211: 123-136, 2000
86. Mittelman SD, Bergman RN: Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin. Am J Physiol Endocrinol Metab 279: E630-E637, 2000
87. Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229, 2002
88. Kwon G, Marshall CA, Liu H, Pappan KL, Remedi MS, McDaniel ML: Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: Effects on cell cycle progression in rodent islets. J Biol Chem 281: 3261-3267, 2006
89. Kwon G, Marshall CA, Pappan KL, Remedi MS, McDaniel ML: Signaling elements involved in the metabolic regulation of mTOR by nutrients, incretins, and growth factors in islets. Diabetes 53[Suppl 3]: S225-S232, 2004
90. Bussiere CT, Lakey JR, Shapiro AM, Korbutt GS: The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 49: 2341-2349, 2006
91. Rubenstein AH, Mako ME, Horwitz DL: Insulin and the kidney. Nephron 15: 306-326, 1975
92. Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 27: 351-357, 1984
93. Snyder RW, Berns JS: Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 17: 365-370, 2004
94. Johnson CP, Gallagher-Lepak S, Zhu YR, Porth C, Kelber S, Roza AM, Adams MB: Factors influencing weight gain after renal transplantation. Transplantation 56: 822-827, 1993
95. Pfeiffer T, Albrecht KH, Wagner K, Herget S, Eigler FW: The effect of obesity on outcome of kidney transplantation [in German]. Med Klin (Munich) 89: 635-639, 1994
96. Thoma B, Grover VK, Shoker A: Prevalence of weight gain in patients with better renal transplant function. Clin Nephrol 65: 408-414, 2006
97. Dengel DR, Kelly AS, Olson TP, Kaiser DR, Dengel JL, Bank AJ: Effects of weight loss on insulin sensitivity and arterial stiffness in overweight adults. Metabolism 55: 907-911, 2006
98. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL: Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133: 592-599, 2000
99. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J: High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 19: 998-1000, 1996
100. Ozyilkan E, Erbas T, Simsek H, Telatar F, Kayhan B, Telatar H: Increased prevalence of hepatitis C virus antibodies in patients with diabetes mellitus. J Intern Med 235: 283-284, 1994
101. Gray H, Wreghitt T, Stratton IM, Alexander GJ, Turner RC, O'Rahilly S: High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabet Med 12: 244-249, 1995
102. Bloom RD, Lake JR: Emerging issues in hepatitis C virus-positive liver and kidney transplant recipients. Am J Transplant 6: 2232-2237, 2006
103. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N: Impaired IRS-1/ PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology 38: 1384-1392, 2003
104. Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, Baba S, Koga H, Kumashiro R, Ueno T, Ogata H, Yoshimura A, Sata M: Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol 165: 1499-1508, 2004
105. Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, Lupi R, Del Guerra S, Bugliani M, Torri S, Del Prato S, Mosca F, Filipponi F, Marchetti P: Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care 28: 940-941, 2005
106. Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, Bhan A, Baid S, Cosimi AB, Pascual M, Chung RT: Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation 77: 703-710, 2004
107. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC: Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. J Am Soc Nephrol 13: 1374-1380, 2002
108. Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, Herrmann G, Berger A, Kusterer K, Teuber G, Cobelli C, Usadel KH: Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. Eur J Clin Invest 30: 111-121, 2000
109. Gursoy M, Koksal R. Karavelioglu D, Colak T, Gur G, Ozdemir N, Boyacioglu S, Bilgin N: Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients. Transplant Proc 32: 580-582, 2000
110. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D, Rostaing L: Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 14: 2092-2098, 2003
111. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-853, 1998
112. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 854-865, 1998
113. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329: 977-986, 1993
114. Armstrong KA, Prins JB, Beller EM, Campbell SB, Hawley CM, Johnson DW, Isbel NM: Should an oral glucose tolerance test be performed routinely in all renal transplant recipients? Clin J Am Soc Nephrol 1: 100-108, 2006
115. Marchetti P: New-onset diabetes after liver transplantation: From pathogenesis to management. Liver Transpl 11: 612-620, 2005
116. Lehrke M, Lazar MA: The many faces of PPARgamma. Cell 123: 993-999, 2005
117. Watanabe I, Tani S, Anazawa T, Kushiro T, Kanmatsuse K: Effect of pioglitazone on arteriosclerosis in comparison with that of glibenclamide. Diabetes Res Clin Pract 68: 104-110, 2005
118. Qayyum R, Schulman P: Cardiovascular effects of the thiazolidinediones. Diabetes Metab Res Rev 22: 88-97, 2006
119. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J; PROactive investigators: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366: 1279-1289, 2005
120. Kaplan B, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini L, Mulgaonkar SP: Potential interaction of troglitazone and cyclosporine. Transplantation 65: 1399-1400, 1998
121. Villanueva G, Baldwin D: Rosiglitazone therapy of post-transplant diabetes mellitus. Transplantation 80: 1402-1405, 2005
122. Luther P, Baldwin D Jr: Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 4: 2135-2138, 2004
123. Baldwin D Jr, Duffin KE: Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 77: 1009-1014, 2004
124. Pietruck F, Kribben A, Van TN, Patschan D, Herget-Rosenthal S, Janssen O, Mann K, Philipp T, Witzke O: Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplantation. Transpl Int 18: 483-486, 2005
125. Turk T, Pietruck F, Dolff S, Kribben A, Janssen OE, Mann K, Philipp T, Heemann U, Witzke O: Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 6: 842-846, 2006
126. Kendall DM, Kim D, Maggs D: Incretin mimetics and dipeptidyl peptidase-IV inhibitors: A review of emerging therapies for type 2 diabetes. Diabetes Technol Ther 8: 385-396, 2006
127. Miller S, St Onge EL: Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother 40: 1336-1343, 2006
128. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20: 537-544, 1997
129. Prasad GV, Kim SJ, Huang M, Nash MM, Zaltzman JS, Fenton SS, Cattran DC, Cole EH, Cardella CJ: Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins). Am J Transplant 4: 1897-1903, 2004
130. Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, Levin A, Masri B, Parekh R, Wanner C, Wheeler DC, Wilson PW; National Kidney Foundation: Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 4[Suppl 7]: 13-53, 2004
131. Scheen AJ: Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30: 498-505, 2004
132. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR: Effect of ramipril on the incidence of diabetes. N Engl J Med 355: 1551-1562, 2006